Standard Article

Prostate Cancer Prevention Trial

  1. Alon Z. Weizer,
  2. Maha H. Hussain

Published Online: 13 JUN 2008

DOI: 10.1002/9780471462422.eoct629

Wiley Encyclopedia of Clinical Trials

Wiley Encyclopedia of Clinical Trials

How to Cite

Weizer, A. Z. and Hussain, M. H. 2008. Prostate Cancer Prevention Trial. Wiley Encyclopedia of Clinical Trials. 1–7.

Author Information

  1. University of Michigan, Ann Arbor, Michigan

Publication History

  1. Published Online: 13 JUN 2008

Abstract

Prostate cancer is the most common malignancy diagnosed and the second most common cause of cancer death in American men. Although effective treatment strategies exist, the prolonged natural history of the disease makes prevention attractive. Androgens are involved in the development and progression of prostate cancer. Finasteride (a 5-alpha-reductase inhibitor) prevents the conversion of testosterone to dihydrotestosterone within the prostate decreasing prostate growth. The Prostate Cancer Prevention Trial randomized 18,882 men 55 years or older to finasteride versus placebo in order to assess the medication's ability to decrease the prevalence of prostate cancer over a seven-year period. Finasteride resulted in a 24.8% reduction in the prevalence of prostate cancer; however, men diagnosed with prostate cancer in the treatment arm were found to have higher grade prostate cancer. Secondary data analyses have sought explanations for this finding as well as provided additional insight into the use of prostate-specific antigen in clinical practice.

Keywords:

  • Prostatic Neoplasms;
  • Chemoprevention;
  • Testosterone 5-Alpha-Reductase;
  • Prostate-Specific Antigen;
  • Prostate Biopsy